Discover how quantitative proteomics is revolutionizing neuroblastoma research by revealing synergistic drug combinations that target cancer cell vulnerabilities.
Groundbreaking research reveals how stathmin protein hijacks the actin cytoskeleton to drive neuroblastoma metastasis in children.